Cytokine-mediated modulation of inflammation by leukocytes

Cytokine-mediated modulation of inflammation by leukocytes is a complex biological process rather than a single molecular target. It encompasses the production and secretion of signaling proteins, known as cytokines, by various white blood cells—including macrophages, T lymphocytes, and neutrophils—to regulate the immune system's response to injury or infection (Source: Nature Reviews Immunology). Key pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) bind to specific receptors on target cells, initiating intracellular signaling cascades like the JAK-STAT pathway that drive the inflammatory phenotype (Source: PubMed, PMID: 17504532). While essential for host defense, the dysregulation of this process leads to chronic inflammation and tissue destruction characteristic of autoimmune diseases like rheumatoid arthritis and Crohn's disease (Source: NIH, NIAID). Pharmacological strategies typically target individual components of this pathway, such as specific cytokines or their receptors, to dampen the overactive immune response. Because this term describes a broad physiological mechanism involving multiple distinct proteins, it is classified as a biological process or pathway rather than a discrete therapeutic target (Source: UniProt).

Other names

Cytokine signaling in inflammationLeukocyte-mediated inflammatory responseCytokine-driven immune modulationInflammatory cytokine pathway

Therapeutic intervention involves the neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6), competitive blockade of their respective cell-surface receptors, or the inhibition of downstream intracellular signaling components such as Janus kinases (JAKs) to prevent the transcription of inflammatory genes (Source: StatPearls, NCBI).